Immunogens for hiv vaccination

A method of treating or preventing a human immunodeficiency virus (HIV) infection or a disease associated with an HIV infection in a subject in need thereof, the method comprising administering to the subject an immunogenic polypeptide or a nucleic acid encoding the immunogenic polypeptide,

• wherein the immunogenic polypeptide comprises:
• i) a sequence having at least 90% identity to the sequence of SEQ ID NO:1,
• ii) a sequence having at least 90% identity to the sequence of SEQ ID NO:2,
• iii) a sequence having at least 90% identity to the sequence of SEQ ID NO:3,
• iv) a sequence having at least 90% identity to the sequence of SEQ ID NO:4,
• v) a sequence having at least 90% identity to the sequence of SEQ ID NO:5,
• vi) a sequence having at least 90% identity to the sequence of SEQ ID NO:6,
• vii) a sequence having at least 90% identity to the sequence of SEQ ID NO:7,
• viii) a sequence having at least 90% identity to the sequence of SEQ ID NO:8,
• ix) a sequence having at least 90% identity to the sequence of SEQ ID NO:9,
• x) a sequence having at least 90% identity to the sequence of SEQ ID NO:10,
• xi) a sequence having at least 90% identity to the sequence of SEQ ID NO:11,
• xii) a sequence having at least 90% identity to the sequence of SEQ ID NO:12,
• xiii) a sequence having at least 90% identity to the sequence of SEQ ID NO:13,
• xiv) a sequence having at least 90% identity to the sequence of SEQ ID NO:14,
• xv) a sequence having at least 90% identity to the sequence of SEQ ID NO:15, and
• xvi) a sequence having at least 90% identity to the sequence of SEQ ID NO:16,
• wherein at least two of the sequences of i)-xvi) are joined by an amino acid linker, and
• wherein the immunogenic polypeptide or the nucleic acid encoding the immunogenic polypeptide is administered in an amount effective for eliciting inducing an immune response against HIV in the subject.

A method of treating or preventing an HIV infection or a disease associated with an HIV infection in a human subject in need thereof, the method comprising administering to the human subject an immunogenic polypeptide or a nucleic acid encoding the immunogenic polypeptide,

• wherein the immunogenic polypeptide comprises:
• i) the sequence of SEQ ID NO:1 or a sequence derived from the sequence of SEQ ID NO:1 by one or more conservative amino acid substitutions,
• ii) the sequence of SEQ ID NO:2 or a sequence derived from the sequence of SEQ ID NO:2 by one or more conservative amino acid substitutions,
• iii) the sequence of SEQ ID NO:3 or a sequence derived from the sequence of SEQ ID NO:3 by one or more conservative amino acid substitutions,
• iv) the sequence of SEQ ID NO:4 or a sequence derived from the sequence of SEQ ID NO:4 by one or more conservative amino acid substitutions,
• v) the sequence of SEQ ID NO:5 or a sequence derived from the sequence of SEQ ID NO:5 by one or more conservative amino acid substitutions,
• vi) the sequence of SEQ ID NO:6 or a sequence derived from the sequence of SEQ ID NO:6 by one or more conservative amino acid substitutions,
• vii) the sequence of SEQ ID NO:7 or a sequence derived from the sequence of SEQ ID NO:7 by one or more conservative amino acid substitutions,
• viii) the sequence of SEQ ID NO:8 or a sequence derived from the sequence of SEQ ID NO:8 by one or more conservative amino acid substitutions,
• ix) the sequence of SEQ ID NO:9 or a sequence derived from the sequence of SEQ ID NO:9 by one or more conservative amino acid substitutions,
• x) the sequence of SEQ ID NO:10 or a sequence derived from the sequence of SEQ ID NO:10 by one or more conservative amino acid substitutions,
• xi) the sequence of SEQ ID NO:11 or a sequence derived from the sequence of SEQ ID NO:11 by one or more conservative amino acid substitutions,
• xii) the sequence of SEQ ID NO:12 or a sequence derived from the sequence of SEQ ID NO:12 by one or more conservative amino acid substitutions,
• xiii) the sequence of SEQ ID NO:13 or a sequence derived from the sequence of SEQ ID NO:13 by one or more conservative amino acid substitutions,
• xiv) the sequence of SEQ ID NO:14 or a sequence derived from the sequence of SEQ ID NO:14 by one or more conservative amino acid substitutions,
• xv) the sequence of SEQ ID NO:15 or a sequence derived from the sequence of SEQ ID NO:15 by one or more conservative amino acid substitutions, and
• xvi) the sequence of SEQ ID NO:16 or a sequence derived from the sequence of SEQ ID NO:16 by one or more conservative amino acid substitutions,
• wherein at least two of the sequences of i)-xvi) are joined by an amino acid linker, and
• wherein the immunogenic polypeptide or the nucleic acid encoding the immunogenic polypeptide is administered in an amount effective for eliciting an immune response against HIV in the human subject.

A method of treating or preventing an HIV infection or a disease associated with an HIV infection in a subject in need thereof, the method comprising sequentially administering to the subject (1) a first immunogenic polypeptide or a nucleic acid encoding the first immunogenic polypeptide, and (2) a second immunogenic polypeptide or a nucleic acid encoding the second immunogenic polypeptide,

• wherein the first immunogenic polypeptide comprises the sequences of SEQ ID NOs:1-16 adjoined by amino acid linkers,
• wherein the second immunogenic polypeptide comprises the sequences of SEQ ID NOs:1-16 adjoined by amino acid linkers,
• wherein the nucleic acid encoding the first immunogenic polypeptide is administered to the subject as part of an expression cassette, an expression vector, a virus, or a cell,
• wherein the nucleic acid encoding the second immunogenic polypeptide is administered to the subject as part of an expression cassette, an expression vector, a virus, or a cell, and
• wherein the first and second immunogenic polypeptides or nucleic acids encoding the first and second immunogenic polypeptides are administered in amounts effective for eliciting an immune response against HIV in the subject.

A method of eliciting an immune response against HIV in a human subject in need thereof, the method comprising administering to the human subject an immunogenic polypeptide or a nucleic acid encoding the immunogenic polypeptide,

• wherein the immunogenic polypeptide comprises:
• i) a sequence having at least 90% identity to the sequence of SEQ ID NO:1,
• ii) a sequence having at least 90% identity to the sequence of SEQ ID NO:2,
• iii) a sequence having at least 90% identity to the sequence of SEQ ID NO:3,
• iv) a sequence having at least 90% identity to the sequence of SEQ ID NO:4,
• v) a sequence having at least 90% identity to the sequence of SEQ ID NO:5,
• vi) a sequence having at least 90% identity to the sequence of SEQ ID NO:6,
• vii) a sequence having at least 90% identity to the sequence of SEQ ID NO:7,
• viii) a sequence having at least 90% identity to the sequence of SEQ ID NO:8,
• ix) a sequence having at least 90% identity to the sequence of SEQ ID NO:9,
• x) a sequence having at least 90% identity to the sequence of SEQ ID NO:10,
• xi) a sequence having at least 90% identity to the sequence of SEQ ID NO:11,
• xii) a sequence having at least 90% identity to the sequence of SEQ ID NO:12,
• xiii) a sequence having at least 90% identity to the sequence of SEQ ID NO:13,
• xiv) a sequence having at least 90% identity to the sequence of SEQ ID NO:14,
• xv) a sequence having at least 90% identity to the sequence of SEQ ID NO:15, and
• xvi) a sequence having at least 90% identity to the sequence of SEQ ID NO:16,
• wherein at least two of the sequences of i)-xvi) are joined by an amino acid linker.